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Abstract
The status of glycoconjugates (protein bound hexose, hexosamine, sialic acid and fucose) in plasma or serum serve as
potential biomarkers for assessing tumor progression and therapeutic interventions. Aim of the present study was to
investigate the protective effect of two major soy isoflavones, genistein and daidzein, in combination on the status of
glycoconjugates in plasma, erythrocyte membrane and mammary tissues during 7,12-dimethylbenz[a]anthracene (DMBA)
induced mammary carcinogenesis in female Sprague-Dawley rats. A single subcutaneous injection of DMBA (25 mg rat-1) in
the mammary gland developed mammary carcinoma in female Sprague-Dawley rats. Elevated levels of plasma and
mammary tissue glycoconjugates accompanied by reduction in erythrocyte membrane glycoconjugates were observed in rats
bearing mammary tumors. Oral administration of genistein + daidzein (20 mg + 20 mg kg-1 bw/day) to DMBA treated rats
significantly (p< 0.05) brought back the status of glycoconjugates to near normal range. The present study thus demonstrated
that genistein and daidzein in combination protected the structural integrity of the cell surface and membranes during
DMBA-induced mammary carcinogenesis.
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Introduction
Glycosylation of proteins has been shown to have significant impact on protein function and confirmation (Yang and
Hancock, 2004). Hexoses, fucose and sialic acid form the monosaccharide units of the oligosaccharides that are attached to
proteins. More than half of all proteins in human serum are glycosylated (Apweiler et al., 1999). Measurement of serum
glycoconjugates serve as a potential source of disease biomarkers and provides insights into disease pathogenesis (Dube and
Bertozzi, 2005). Altered glycoconjugates levels were reported in many pathological conditions including cancer (Narayana,
1994).
The sialo-glycoconjugates that are expressed on the plasma membrane reflects the surface properties of either normal
or tumor cells (McDonagh and Nathan, 1990). Sialic acid-rich glycoconjugates are over expressed in tumor cells and was
correlated with stages and metastatic potential of tumor cells (Manoharan et al., 2004). Fucose, one of the eight essential
sugars in the body, is essential for optimum cell-to-cell communication (Listinsky et al., 2001). Fucose and mannose have
prominent role in slowing the growth of cancer cells (Rao et al., 1998).
Breast cancer is the most common neoplasm amongst women worldwide (Jemal et al., 2009). Around 1.5 million new
cases and 400, 000 deaths due to breast cancer are reported every year (Hortobagyi et al., 2005). 7,12-
dimethylbenz[a]anthracene (DMBA), a potent organ-specific carcinogen, is commonly used for the induction of mammary
cancer in female Sprague-Dawley rats. Altered glycosylation pattern of proteins has been reported in DMBA- induced
mammary carcinogenesis (Ramprasath et al., 2007).
Genistein and daidzein, the two major isoflavones of soybeans, have been the focus of recent research due to their
promising role in cancer prevention. Diverse pharmacological and biochemical effects of genistein and daidzein including
anticancer potential have been well documented (Sarkar and Li, 2002: Mishra et al., 2009). Genistein and daidzein act as
anticancer agents in part by their ability to scavenge reactive oxygen species generated during carcinogenesis (Ruiz-Larrea et
al., 1997: Ruffer and Kulling, 2006). Previous study from our laboratory has demonstrated the chemopreventive potential of
genistein and daidzein, in combination, during DMBA-induced mammary carcinogenesis. Genistein and daidzein, in
combination, significantly (80%) prevented tumor formation in rats treated with DMBA (Pugalendhi and Manoharan, 2010).
The present study demonstrates the protective effect of genistein and daidzein, in combination, on cellular integrity during
DMBA-induced mammary carcinogenesis in Sprague-Dawley rats
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Materials and Methods
Forty female Sprague-Dawley rats six weeks old were obtained from National Institute of Nutrition, Hyderabad and
maintained in the Central Animal House, Rajah Muthiah Medical College and Hospital, Annamalai University. The
experimental design (Proposal No. 578 dated. 25.07.2008) was approved by the Annamalai University animal ethical
committee (Register number 160/1999/CPCSEA), Annamalainagar. The rats were housed in polypropylene cages at room
temperature (27 ± 2°C) with relative humidity 55 ± 5%, in an experimental room. In Annamalainagar, the LD (light: dark)
cycle is almost 12:12h. The rats were maintained as per the principles and guidelines of the ethical committee for animal care
of Annamalai University in accordance with the Indian National Law on animal care and use. The rats were provided with
standard pellet diet (Amrut Laboratory Animal Feed, Mysore Feeds Limited, Bangalore, India) and water ad libitum.
Chemicals
Genistein and daidzein were purchased from Shaanxi Sciphar Biotechnology Co. Ltd, China. DMBA was obtained
from Sigma-Aldrich Chemicals Pvt. Ltd., Bangalore, India. Other chemicals and solvents used were of analar grade.
Induction of mammary carcinogenesis
Mammary carcinogenesis was induced in Sprague-Dawley rats using a single subcutaneous injection of 25 mg of DMBA in 1
ml emulsion of sunflower oil (0.75 ml) and physiological saline (0.25 ml) to each rat (Kolanjiappan and Manoharan, 2005).
Experimental Design
Forty rats were divided into four groups of ten rats per group. Group 1 rats received the excipient (single dose of 1
ml of emulsion of sunflower oil and physiological saline, s.c) and 1 ml of 2% DMSO (p.o) throughout the
experimental period and served as vehicle treated control. Rats in groups 2 and 3 were induced mammary
carcinogenesis by providing single subcutaneous injection of 25 mg of DMBA in 1 ml of sunflower oil and
physiological saline. Group 2 rats received no other treatment. Group 3 rats were orally administered with genistein +
daidzein (20 mg + 20 mg kg-1 bw/day, dissolved in 2% DMSO) starting one week before the exposure of the carcinogen
and continued till the experimental period. Group 4 rats were orally administered with genistein + daidzein (20 mg + 20
mg kg-1 bw/day, dissolved in 2% DMSO) alone throughout the experimental study. The experiment was terminated at
16th week and all rats were sacrificed by cervical dislocation. Plasma and processed tissues samples were used for
various biochemical estimations.
Biochemical estimations
Blood samples were collected into heparinized tubes. Plasma was separated by centrifugation at 1000 × g for 15
min. Tissue samples from rats were washed with ice cold saline and dried between folds of filter paper, weighed and
homogenized using Tris-HCl buffer (0.1 M, pH 7.4) and used for biochemical estimations. The precipitate obtained
after treating the plasma with 95% ethanol was used for the estimation of protein bound hexose and hexosamine. After
plasma separation, the erythrocyte membrane was isolated by the method of Dodge et al., (1968) modified by Quist
(1980). Similarly, the precipitate obtained after treating the mammary tissues and erythrocyte membranes with 1%
phosphotungstic acid followed by 5% TCA was used for the estimation of protein found hexose and hexosamine. The
protein bound hexose, hexosamine, total sialic acid and fucose were estimated by the methods of Niebes (1972),
Wagner (1979), Warren (1959) and Dische and Shettles (1948) respectively. Plasma lipid bound sialic acid level was
determined by the method of Katopodis and Stock (1980).
Periodic acid-Schiff (PAS) staining
For histopathological studies, tumor and normal mammary tissues were fixed in 10% formalin and were routinely
processed and paraffin embedded 2-3 µm sections were cut in a rotary microtome. The slides containing tissue sections
were immersed in a solution of 0.5% periodic acid for 10 min at 56°C. The slides were washed in running tap water and
immersed in Schiff’s reagent for 40 min. Subsequently, the sections were washed in running tap water for 10 min,
counterstained with hematoxylin, dehydrated in graded ethanol, cleared in xylene and mounted in resinous medium.
Results
The levels of protein bound hexose, hexosamine, total sialic acid, lipid bound sialic acid and fucose in plasma and
mammary tissues of control and experimental rats in each group is shown in table 1 and 2 respectively. The levels of
glycoconjugates were significantly increased in tumor bearing rats as compared to control rats. Oral administration of
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genistein + daidzein to DMBA-induced mammary cancer rat significantly reduced the levels of glycoconjugates. Rats treated
with genistein + daidzein alone showed no significant difference as compared to control rats.
Table 1: Protein bound hexose, hexosamine, total sialic acid, lipid bound sialic acid and fucose in plasma of control and
experimental rats.
Groups Protein boundhexose (mg/dl)
Protein bound
hexosamine
(mg/dl)
Total sialic acid
(mg/dl)
Lipid bound
sialic acid
(mg/dl)
Fucose (mg/dl)
Control
(Vehicle) 104.8±10.2
a 65.40±6.0a 41.80±4.0a 12.2±1.3a 12.64±0.98a
DMBA 135.5±12.62b 94.61±8.8b 67.40±7.1b 23.4±2.4b 21.50±1.9b
DMBA + Genistein + Daidzein 116.4±10.1c 73.2±7.9c 47.1±4.8c 13.9±1.5c 14.10±1.6c
Genistein+ Daidzein alone 103.5±10.4a 65.10±6.5a 41.3±4.1a 12.2±1.2a 12.55±1.0a
Values are expressed as mean ± SD for 10 rats in each group. Values that are not sharing a common superscript letter in the
same column differ significantly differ at p < 0.05 (DMRT).
Table 2: Protein bound hexose, hexosamine, total sialic acid levels in mammary tissues of control and experimental rats.
Groups
Protein bound
hexose
(mg/ g protein)
Protein bound
hexosamine
(mg/ g protein)
Total sialic acid
(mg/ g protein)
Control
(Vehicle) 3.08±0.25
a 2.10±0.21a 1.55±0.12a
DMBA 5.24±0.51b 4.14±0.34b 3.10±0.29b
DMBA+
Genistein+
Daidzein
3.40±0.35c 2.36±0.24c 1.74±0.18c
Genistein+
Daidzein alone 3.08±0.28
a 2.09±0.20a 1.54±0.14a
Values are expressed as mean ± SD for 10 rats in each group. Values that are not sharing a common superscript letter in the
same column differ significantly differ at p < 0.05 (DMRT).
The levels of protein bound hexose, hexosamine, and total sialic acid, in erythrocyte membranes of control and
experimental rats in each group is shown in table 3. The levels of protein bound hexose, hexosamine, and total sialic acid
were significantly decreased in erythrocyte membranes of tumor bearing rats as compared to control rats. Oral administration
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of genistein + daidzein to DMBA-induced mammary cancer rats significantly increased the status of glycoconjugates in
erythrocyte membranes. Rats treated with genistein + daidzein alone showed no significant difference as compared to control
rats.
Table 3: Protein bound hexose, hexosamine, total sialic acid levels in erythrocyte membranes of control and experimental
rats.
Groups
Protein bound
hexose (µg/mg
protein)
Protein bound
hexosamine
(µg/mg protein)
Total sialic acid
(µg/mg protein)
Control
(Vehicle) 106.8±10.24
a 70.14±6.2a 24.04±2.1a
DMBA 82.5±9.10b 53.42±2.7b 16.18±1.7b
DMBA+
Genistein+
Daidzein
96.2±9.26c 63.20±5.9c 21.65±2.0c
Genistein+
Daidzein alone 107.1±10.50
a 71.06±6.1a 24.10±2.2a
Values are expressed as mean ± SD for 10 rats in each group. Values that are not sharing a common superscript letter in the
same column differ significantly differ at p < 0.05 (DMRT).
The glycoconjugates expression pattern using Periodic acid-Schiff (PAS) staining is given in fig 1 (a-c). Over
expression of glycoconjugates was observed in the mammary tissues of tumor bearing rats (fig 1b) as compared to control
rats (fig 1a). Oral administration of genistein + daidzein to DMBA-induced mammary cancer rats decreased the expression of
glycoconjugates (fig 1c). Rats treated with genistein + daidzein alone showed similar pattern of expression as compared to
control rats.
Statistical analysis
The values are expressed as mean ± SD. The statistical comparisons were performed by one way analysis of variance
(ANOVA) followed by Duncan’s multiple range test (DMRT), using SPSS version 12.0 for windows. The values are
considered statistically significant if the p value was less than 0.05.
Discussion
Breast cancer incidence is low in Asian populations than their American counterparts; this has been linked with high
soy consumption. Soy isoflavones, genistein and daidzein have strong antioxidant activity (Guo et al., 2002). Combination of
isoflavones including genistein and daidzein has more pronounced inhibitory effects on breast cancer cell proliferation
(Verma and Goldin, 1998). Flavonoids and isoflavonoids have great potential to modulate the levels of glycoproteins
(Elangovan et al., 1994).
Altered cell surface glycosylation plays crucial role in malignant transformation. Aberrant glycosylation is also involved in
the key steps of neoplastic progression including tumor invasion and evasion of host immunosurveillance (Hakomori, 2002).
Cell surface glycosylation could be used as a source of biomarkers as well as targets for immunotherapy of tumors (Kobata
and Amano, 2005). Ramprasath et al (2007) demonstrated that the levels of hexose and hexosamine were elevated in DMBA-
induced mammary carcinogenesis. Increase in plasma protein-bound hexose, hexosamine and total sialic acid were reported
in cancer patients as well as DMBA-induced experimental carcinogenesis (Patel et al., 1989: Manoharan et al., 2009).
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Figure 1a) Glycoconjugates expression pattern in
mammary tissues of the control rats Figure 1b) Over expression of glycoconjugates in the
mammary tissues of tumor bearing rats
Figure 1c) Decreased expression of
glycoconjugates in DMBA-induced mammary cancer
rats treated with genistein + daidzein.
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It has been suggested that alterations may occur in cell surface and cell membrane glycoproteins, glycolipids, and
enzymic components that synthesize or degrade complex membrane carbohydrate molecules during neoplastic transformation
(Nachbar et al., 1974). In the malignant tumors of the breast, the activities of glycosidases were increased 2–3 times as
compared to normal tissue (Bossmann and Hall, 1974). Increased levels of glycoproteins in tumor cells are probably due to
increased synthesis during carcinogenesis. Previous studies from our laboratory have reported decreased levels of erythrocyte
membrane glycoconjugates in experimental and human cancers (Manoharan et al., 2004 and 2009). The depletion of
erythrocyte membrane glycoconjugates could be due to increased degradation of membranes or decreased synthesis or as a
result of increased shedding into circulation. Increased levels of plasma glycoprotein in tumor bearing rats could therefore be
due to increased shedding from tumor tissues or erythrocytes membrane occurring during carcinogenesis.
Profound studies have demonstrated that sialic acid content was doubled in malignant tumors. Sialic acid (total, lipid
bound or protein bound) levels were higher in patients with cancer as compared to normal subjects. Increased concentrations
of serum and tumor tissues sialic acid were also reported in experimental carcinogenesis (Celil et al., 2003; Senthil et al,
2007; Suresh et al., 2007). Increased turnover of membrane sialoglycoproteins of tumor cell surface increase their
concentration in blood. Fucose plays a significant role in cancer and its spread. Fucose status has potential applications as
diagnostic and prognostic markers (Patel et al., 1994). Fucose helps to inhibit the growth of tumors. Elevated fucose content
in serum and tumor tissues were reported in cancer patients and experimental cancer (Rao et al., 1998: Manoharan et al.,
2009). Increased turnover of sialic acid and fucose could account for increased levels of plasma sialic acid and fucose.
Oral administration of genistein + daidzein to DMBA treated rats significantly brought back the status of
glycoconjugates in plasma, erythrocyte membrane and mammary tissues. Our results thus suggest that genistein and daidzein,
in combination, significantly protected the structural integrity of cell surface and membranes during DMBA-induced
carcinogenesis.
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